Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers

Aktis Oncology, a Massachusetts startup developing targeted radiation drugs for cancer, has raised $84 million in new funds from Merck & Co’s venture arm and other investors. Merck joins Novartis and Bristol Myers Squibb in betting on the biotechnology company, which debuted publicly last year.